163 - Double Trouble: How Viruses and Bacterial Interactions Affect the Pathogenesis of Pneumonia

Friday, October 21, 2022

1:45 PM – 3:00 PM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Anne-Catrin Uhlemann, MD, PhD

Associate Professor of Medicine
Columbia University Irving Medical Center
New York, NY, United States

Disclosure(s): Merck: Grant/Research Support (Ongoing)
Luiz Bermudez, MD

Professor
Oregon State University
Corvallis, OR, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Jonathan McCullers, MD

Senior Executive Associate Dean of Clinical Affairs
U. Tennessee Health Science Center and St. Jude Children’s Research Hospital
Memphis, Tennessee, United States

Disclosure(s): No financial relationships to disclose

Slides
Lucas Hoffman, MD, PhD

Professor
University of Washington
Seattle, WA, United States

Disclosure(s): No financial relationships to disclose

Slides
Richard Wunderink, MD

Professor of Medicine, Pulmonary and Critical Care
Pulmonary and Critical Care
Northwestern University Feinberg School of Medicine
Chicago, IL, United States

Disclosure(s): Bioaegis: Advisor/Consultant (Ongoing); bioMerieux Inc.: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Helixbind: Grant/Research Support (Ongoing); LaJolla Pharmaceutical: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Microbiotix: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Clinical Evaluation Committee (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Synairgen: Advisor/Consultant (Ongoing); Venatorx Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Vir Biotechnology: DSMB (Ongoing)

Slides

Disclosure(s):

Anne-Catrin Uhlemann, MD, PhD: Merck: Grant/Research Support (Ongoing)

Luiz Bermudez, MD: No financial relationships to disclose

Jonathan A. McCullers, MD: No financial relationships to disclose

Lucas Hoffman, MD, PhD: No financial relationships to disclose

Richard G. Wunderink, MD: Bioaegis: Advisor/Consultant (Ongoing); bioMerieux Inc.: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Helixbind: Grant/Research Support (Ongoing); LaJolla Pharmaceutical: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Microbiotix: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Clinical Evaluation Committee (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Synairgen: Advisor/Consultant (Ongoing); Venatorx Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Vir Biotechnology: DSMB (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the role of coinfections in the pathogenesis of influenza;
gain knowledge about microbial interactions and their impact on the onset and the outcome of respiratory infections in patients with cystic fibrosis;
describe how COVID-19 might influence the susceptibility to secondary bacterial infection

Presentations:

1:45 PM – 2:10 PM US ET

Novel Insights Into Influenza and Bacterial Coinfection during Childhood Pneumonia
Speaker: Jonathan A. McCullers, MD – U. Tennessee Health Science Center and St. Jude Children’s Research Hospital
2:10 PM – 2:35 PM US ET

Respiratory Pathogen Interactions in Cystic Fibrosis
Speaker: Lucas Hoffman, MD, PhD – University of Washington
2:35 PM – 3:00 PM US ET

COVID-19 and Bacterial Co-Infection
Speaker: Richard G. Wunderink, MD – Northwestern University Feinberg School of Medicine